Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Account Payables (2017 - 2025)

Historic Change in Account Payables for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $962000.0.

  • Puma Biotechnology's Change in Account Payables rose 11605.74% to $962000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 14587.42%. This contributed to the annual value of -$1.4 million for FY2024, which is 40734.97% down from last year.
  • As of Q3 2025, Puma Biotechnology's Change in Account Payables stood at $962000.0, which was up 11605.74% from -$602000.0 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Change in Account Payables ranged from a high of $8.9 million in Q3 2021 and a low of -$8.9 million during Q4 2021
  • Over the past 5 years, Puma Biotechnology's median Change in Account Payables value was $512000.0 (recorded in 2021), while the average stood at -$299473.7.
  • The largest annual percentage gain for Puma Biotechnology's Change in Account Payables in the last 5 years was 106701.71% (2021), contrasted with its biggest fall of 186305.31% (2021).
  • Quarter analysis of 5 years shows Puma Biotechnology's Change in Account Payables stood at -$8.9 million in 2021, then rose by 4.35% to -$8.5 million in 2022, then soared by 121.54% to $1.8 million in 2023, then tumbled by 209.41% to -$2.0 million in 2024, then skyrocketed by 148.1% to $962000.0 in 2025.
  • Its Change in Account Payables was $962000.0 in Q3 2025, compared to -$602000.0 in Q2 2025 and $517000.0 in Q1 2025.